Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation

Basic Research in Cardiology

Volumn 100, Issue 1, 2005, Pages 57-63

  Yang, Xi Ming ^a   Philipp, Sebastian ^a   Downey, James M ^a   Cohen, Michael V ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Ischemia reperfusion; ODQ; Postconditioning; SPT; Wortmannin

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; THEOPHYLLINE; TRIPHENYLTETRAZOLIUM; WORTMANNIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CELL; BLOOD GROUP; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; LEUKOCYTE; MALE; NONHUMAN; RABBIT; RECEPTOR OCCUPANCY; REPERFUSION; SIGNAL TRANSDUCTION; STAINING; STATISTICAL ANALYSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; FEMALE; GUANYLATE CYCLASE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; RABBITS; RECEPTORS, PURINERGIC P1;

EID: 11244270630     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00395-004-0498-4     Document Type: Article

References (22)

1. Baxter GF, Ebrahim Z, Yellon DM (2000) Amp579, an A1/A2A agonist, limits infarct size at reperfusion via a p42/p44MAPK-dependent pathway. Circulation 102:II-212 (Abstract)
2. Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM (2001) Cardio-protective effects of transforming growth factor-β1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 38:930-939
3. Bell RM, Yellon DM (2003) Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: The role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35:185-193
4. Budde JM, Velez DA, Zhao Z-Q, Clark KL, Morris CD, Muraki S, Guyton RA, Vinten-Johansen J (2000) Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc Res 47:294-305
5. Gross ER, Hsu AK, Gross GJ (2004) Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reperfusion in intact rat hearts. Circ Res 94:960-966
6. Hausenloy DJ, Mocanu MM, Yellon DM (2004) Cross-talk between the survival kinases during early reperfusion: Its contribution to ischemic preconditioning. Cardiovasc Res 63:305-312
7. Heusch G (2004) Postconditioning: Old wine in a new bottle? J Am Coll Cardiol 44:1111-1112
8. Jonassen AK, Sack MN, Mjøs OD, Yellon DM (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191-1198
9. Kin H, Zhao Z-Q, Sun H-Y, Wang N-P, Corvera JS, Halkos ME, Kerendi F, Guyton RA, Vinten-Johansen J (2004) Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62:74-85
10. Liao Z, Brar BK, Cai Q, Stephanou A, O'Leary RM, Pennica D, Yellon DM, Latchman DS (2002) Cardiotrophin-1(CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res 53:902-910
11. Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM (1991) Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84:350-356
12. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136
13. National Research Council (1996) Guide for the Care and Use of Laboratory Animals. 7th ed. National Academy Press, Washington, D. C.
14. Smits GJ, McVey M, Cox BF, Perrone MH, Clark KL (1998) Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther 286:611-618
15. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004) Postconditioning: A form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95:230-232
16. Xu Z, Downey JM, Cohen MV (2001) AMP 579 reduces contracture and limits infarction in rabbit heart by activating adenosine A2 receptors. J Cardiovasc Pharmacol 38:474-481
17. Xu Z, Downey JM, Cohen MV (2003) Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis 5:368-371
18. Xu Z, Yang X-M, Cohen MV, Neumann T, Heusch G, Downey JM (2000) Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion. J Mol Cell Cardiol 32:2339-2347
19. Yang X-M, Krieg T, Cui L, Downey JM, Cohen MV (2004) NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36:411-421
20. Yang X-M, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV (2004) Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44:1103-1110
21. Zhang SJ, Yang X-M, Liu GS, Cohen MV, Pemberton K, Downey JM (2003) CGX-1051, a peptide from Conus snail venom, attenuates infarction in rabbit hearts when administered at reperfusion. J Cardiovasc Pharmacol 42:764-771
22. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA, Vinten-Johansen J (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol 285:H579-H588